{"id":"https://openalex.org/W89747376","doi":null,"title":"Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study.","display_name":"Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study.","alternate_titles":[],"publication_year":1996,"publication_date":"1996-08-01","ids":{"openalex":"https://openalex.org/W89747376","mag":"89747376","pmid":"https://pubmed.ncbi.nlm.nih.gov/8856622"},"language":"en","primary_location":{"id":"pmid:8856622","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8856622","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of rheumatology","raw_type":"Clinical Trial"},"parent_works":[],"lineage":["https://openalex.org/W89747376"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036530922","display_name":"Pawe\u0142 Hrycaj","orcid":"https://orcid.org/0000-0003-1253-8062","observed_orcids":["https://orcid.org/0000-0003-1253-8062"]},"institutions":[{"id":"https://openalex.org/I4210108154","display_name":"Hochrhein Institut f\u00fcr Rehabilitationsforschung","ror":"https://ror.org/01jy3gh06","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4210108154"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"P Hrycaj","raw_affiliation_strings":["Hochrhein Institute for Rehabilitation Research, Bad S\u00e4ckingen, Germany/Rheinfelden, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hochrhein Institute for Rehabilitation Research, Bad S\u00e4ckingen, Germany/Rheinfelden, Switzerland","institution_ids":["https://openalex.org/I4210108154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110679157","display_name":"Th. Stratz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Stratz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064545932","display_name":"P Mennet","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P Mennet","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110622459","display_name":"Wolfgang M\u00fcller","orcid":"https://orcid.org/0000-0001-6474-3733","observed_orcids":["https://orcid.org/0000-0001-6474-3733"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W M\u00fcller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.624,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.81757055,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"23","issue":"8","first_page":"1418","last_page":"1423"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11282","display_name":"Fibromyalgia and Chronic Fatigue Syndrome Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11282","display_name":"Fibromyalgia and Chronic Fatigue Syndrome Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10196","display_name":"Pain Mechanisms and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10365","display_name":"Gastrointestinal motility and disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ondansetron","display_name":"ondansetron","score":0.9150000214576721},{"id":"https://openalex.org/keywords/primary-fibromyalgia","display_name":"primary fibromyalgia","score":0.796999990940094},{"id":"https://openalex.org/keywords/5-ht3-receptor-antagonists","display_name":"5-HT3 receptor antagonists","score":0.9160000085830688},{"id":"https://openalex.org/keywords/serotonin","display_name":"serotonin","score":0.7139999866485596},{"id":"https://openalex.org/keywords/paracetamol","display_name":"paracetamol","score":0.8299999833106995},{"id":"https://openalex.org/keywords/pain-threshold","display_name":"pain threshold","score":0.6940000057220459},{"id":"https://openalex.org/keywords/tender-points","display_name":"tender points","score":0.9700000286102295},{"id":"https://openalex.org/keywords/headache","display_name":"headache","score":0.906000018119812},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.7440000176429749},{"id":"https://openalex.org/keywords/functional-symptoms","display_name":"functional symptoms","score":0.5289999842643738}],"concepts":[{"id":"https://openalex.org/C2777170512","wikidata":"https://www.wikidata.org/wiki/Q410011","display_name":"Ondansetron","level":3,"score":0.9769159555435181},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.901037871837616},{"id":"https://openalex.org/C14184104","wikidata":"https://www.wikidata.org/wiki/Q1362526","display_name":"Visual analogue scale","level":2,"score":0.6323843598365784},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.5854421257972717},{"id":"https://openalex.org/C2777831278","wikidata":"https://www.wikidata.org/wiki/Q540571","display_name":"Fibromyalgia","level":2,"score":0.4729176163673401},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42482930421829224},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.42337143421173096},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.4218016266822815},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.32202816009521484},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11509290337562561}],"mesh":[{"descriptor_ui":"D000082","descriptor_name":"Acetaminophen","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005356","descriptor_name":"Fibromyalgia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010147","descriptor_name":"Pain Measurement","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D012701","descriptor_name":"Serotonin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D017294","descriptor_name":"Ondansetron","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:8856622","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8856622","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of rheumatology","raw_type":"Clinical Trial"},{"id":"mag:89747376","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8856622","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2467860722","https://openalex.org/W2171487934","https://openalex.org/W177412553","https://openalex.org/W165643194","https://openalex.org/W2081817123","https://openalex.org/W2488995615","https://openalex.org/W2127736158","https://openalex.org/W2083722398","https://openalex.org/W2006487768","https://openalex.org/W2059417005"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"study":[2,27],"the":[3,62,69,186,195,252,255],"efficacy":[4],"of":[5,28,64,231,240],"5-hydroxytryptamine":[6],"type":[7],"3":[8],"receptor":[9],"(5-HT-3R)":[10],"antagonist":[11],"(ondansetron)":[12],"vs":[13],"paracetamol":[14],"in":[15,86,131,194,206,215,228,254],"primary":[16],"fibromyalgia":[17],"(FM)":[18],"syndrome.":[19],"METHODS:":[20],"A":[21,83],"double":[22],"blind,":[23],"crossover,":[24],"latin":[25],"square":[26],"21":[29],"patients":[30,145,232,241],"with":[31,114,121,233,242,249],"FM.":[32,234],"Visual":[33],"analog":[34],"scale":[35],"(VAS)":[36],"and":[37,68,105,138,164,170,199,247],"body":[38],"drawings":[39],"were":[40,48,76,192],"used":[41],"to":[42,60,150,179,223,251],"record":[43],"pain":[44,71,87,95,107,156,165,173],"intensity.":[45],"Functional":[46],"symptoms":[47,134],"determined":[49],"for":[50],"using":[51],"a":[52,79,171,203],"Likert-type":[53],"self-developed":[54],"protocol.":[55],"Quantitative":[56],"dolorimetry":[57],"was":[58,112,119,127,153,213],"applied":[59],"assess":[61],"number":[63],"painful":[65],"tender":[66,100],"points":[67,101],"average":[70,106],"threshold.":[72],"Serum":[73],"serotonin":[74,196,208],"levels":[75],"measured":[77,89,158],"by":[78,90,159],"commercial":[80],"ELISA.":[81],"RESULTS:":[82],"marked":[84],"improvement":[85,118],"intensity":[88,140,157],"VAS":[91,160],"(p":[92,97,102,109,135,141,161,167,175,210],"<":[93,98,103,110,136,142,162,168,176,211],"0.005),":[94],"score":[96,166],"0.05),":[99,104],"threshold":[108,174],"0.01)":[111,137,212],"obtained":[113],"ondansetron,":[115],"whereas":[116],"no":[117,189],"seen":[120,193],"paracetamol.":[122],"After":[123],"ondansetron":[124,151,218],"treatment,":[125],"there":[126,152],"also":[128],"significant":[129,190,204],"reduction":[130],"both":[132],"functional":[133],"headache":[139],"0.05).":[143],"In":[144,185],"who":[146,181],"did":[147,182],"not":[148],"respond":[149,183],"higher":[154],"baseline":[155],"0.05)":[163,177],"0.01),":[169],"lower":[172],"compared":[178],"those":[180],"well.":[184],"responsive":[187],"group,":[188],"differences":[191],"level":[197],"before":[198],"after":[200,217],"therapy.":[201],"Whereas":[202],"increase":[205],"serum":[207],"concentration":[209],"observed":[214],"nonresponders":[216],"treatment.":[219],"CONCLUSION:":[220],"Ondansetron":[221],"appears":[222],"be":[224,237],"an":[225],"effective":[226],"drug":[227],"about":[229],"50%":[230],"There":[235],"may":[236],"2":[238],"subsets":[239],"FM":[243],"that":[244],"differ":[245],"clinically":[246],"pathogenetically":[248],"regard":[250],"disturbance":[253],"5-HT-3R":[256],"system.":[257]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W89747376","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
